

M J Gooderham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1881143/publications.pdf>

Version: 2024-02-01

104
papers

5,875
citations

126858

33
h-index

79644

73
g-index

104
all docs

104
docs citations

104
times ranked

4530
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term topical management of psoriasis: the road ahead. <i>Journal of Dermatological Treatment</i> , 2022, 33, 111-120.	1.1	37
2	TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. <i>International Journal of Dermatology</i> , 2022, 61, 139-147.	0.5	23
3	Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 77-85.	0.6	21
4	Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. <i>International Journal of Dermatology</i> , 2022, 61, 746-754.	0.5	15
5	Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A <i>post hoc</i> analysis of PSO-LONG. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 60-67.	1.3	6
6	The effectiveness of intralesional <i>Candida</i> antigen immunotherapy as a treatment for anogenital warts: a retrospective chart review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
7	Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	7
8	Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting. <i>British Journal of Dermatology</i> , 2022, 186, 726-728.	1.4	3
9	Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. <i>Journal of Dermatology</i> , 2022, 49, 95-105.	0.6	11
10	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	1.4	30
11	Visual Dermatology: Achenbach Syndrome (Paroxysmal Finger Hematoma). <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, , 120347542110733.	0.6	0
12	Diagnosis of Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 31-38.	3.3	21
13	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 727-740.	1.4	9
14	Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865.	1.3	11
15	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
16	Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, , 120347542210885.	0.6	1
17	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. <i>Dermatology and Therapy</i> , 2022, 12, 253-265.	1.4	2
18	Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 35-43.	0.3	1

#	ARTICLE	IF	CITATIONS
19	Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2692-2694.	1.1	3
20	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. <i>Dermatology and Therapy</i> , 2022, 12, 1073-1089.	1.4	1
21	Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5-year data from <i>reSURFACE</i> 1 and <i>reSURFACE</i> 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1774-1783.	1.3	7
22	High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1308-1317.	1.3	4
23	Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 117-121.	0.3	0
24	Practice Patterns Around the Management of Atopic Dermatitis in 2018 and 2020. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, , 120347542210996.	0.6	0
25	Topical PDE-4 Inhibitors are Emerging for Psoriasis Treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 109-110.	0.6	3
26	Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23. <i>JAAD Case Reports</i> , 2021, 7, 60-61.	0.4	12
27	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blind trial*. <i>British Journal of Dermatology</i> , 2021, 184, 1047-1058.	1.4	58
28	Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatological Treatment</i> , 2021, 32, 484-491.	1.1	4
29	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806.	1.3	6
30	Phosphodiesterase-4 Inhibition in Psoriasis. <i>Psoriasis: Targets and Therapy</i> , 2021, Volume 11, 21-29.	1.2	21
31	Psoriasis Prevalence and Severity by Expert Elicitation. <i>Dermatology and Therapy</i> , 2021, 11, 1053-1064.	1.4	28
32	Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 576-583.e4.	0.5	16
33	Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland. <i>Journal of Dermatological Treatment</i> , 2021, , 1-19.	1.1	3
34	Real-world experience with risankizumab in patients with plaque psoriasis: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e685-e688.	1.3	5
35	Lymantria dispar dispar (Gypsy) Moth Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 555-556.	0.6	3
36	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 142-152.	13.9	173

#	ARTICLE	IF	CITATIONS
37	Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2431-2439.	1.3	13
38	Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review. <i>Dermatologic Therapy</i> , 2021, 34, e15104.	0.8	7
39	Reverse koebnerization of primary cutaneous follicle center lymphoma following skin biopsy. <i>JAAD Case Reports</i> , 2021, 16, 149-151.	0.4	1
40	A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110349.	0.2	4
41	Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110394.	0.2	7
42	TYK2 inhibition: changing the treatment landscape for psoriasis?. <i>Expert Review of Clinical Immunology</i> , 2021, , 1-3.	1.3	4
43	Return of <i>Lymantria dispar dispar</i> (gypsy moth): A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110579.	0.2	2
44	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020, 182, 1359-1368.	1.4	20
45	An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12. <i>British Journal of Dermatology</i> , 2020, 183, 52-59.	1.4	2
46	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blind trial. <i>British Journal of Dermatology</i> , 2020, 182, 1348-1358.	1.4	117
47	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	1.4	51
48	Trial of Roflumilast Cream for Chronic Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2020, 383, 229-239.	13.9	71
49	Uncommon Adverse Effects of Deoxycholic Acid Injection for Submental Fullness: Beyond the Clinical Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 619-624.	0.6	7
50	Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 911-917.	1.9	4
51	Real-world experience of dupilumab in the treatment of moderate-to-severe atopic dermatitis. <i>International Journal of Dermatology</i> , 2020, 59, e361-e363.	0.5	5
52	Abrocitinib for the treatment of atopic dermatitis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 955-962.	1.3	21
53	Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 863.	2.0	247
54	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1282-1293.	0.6	214

#	ARTICLE	IF	CITATIONS
55	Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 3S-14S.	0.6	16
56	Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 588-595.	0.6	29
57	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	1.4	40
58	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 649.	2.0	120
59	Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 734-740.	0.4	13
60	Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. <i>Drugs in Context</i> , 2020, 9, 1-9.	1.0	43
61	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 394, 576-586.	6.3	198
62	An update on generalized pustular psoriasis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 907-919.	1.3	122
63	Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 5S-10S.	0.6	8
64	Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2019, 155, 1371.	2.0	174
65	The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 289-297.	0.6	15
66	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019, 46, 751-754.	1.0	22
67	Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e350-e352.	1.3	5
68	The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 298-306.	0.6	43
69	Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1982962.	0.2	4
70	Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 282-288.	0.6	3
71	The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 428-435.	0.6	12
72	Dupilumab: A review of its use in the treatment of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, S28-S36.	0.6	218

#	ARTICLE	IF	CITATIONS
73	Shifting the focus â€” the primary role of IL-23 in psoriasis and other inflammatory disorders. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1111-1119.	1.3	80
74	Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). British Journal of Dermatology, 2018, 178, 1315-1323.	1.4	44
75	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Journal of Cutaneous Medicine and Surgery, 2018, 22, 78-83.	0.6	17
76	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the American Academy of Dermatology, 2018, 78, 70-80.	0.6	78
77	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 21S-29S.	0.6	17
78	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 30S-35S.	0.6	9
79	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Journal of Cutaneous Medicine and Surgery, 2018, 22, 3S-5S.	0.6	5
80	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. New England Journal of Medicine, 2018, 379, 1313-1321.	13.9	301
81	Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evidence, 2018, Volume 13, 13-20.	4.7	41
82	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. British Journal of Dermatology, 2018, 179, 615-622.	1.4	57
83	Brodalumab: A Review of Safety. Skin Therapy Letter, 2018, 23, 1-3.	0.3	7
84	Alitretinoin: An Update of Real-World Evidence in The Management of Chronic Hand Dermatitis. Skin Therapy Letter, 2018, 23, 1-4.	0.3	0
85	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine, 2017, 376, 1551-1560.	13.9	413
86	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 2287-2303.	6.3	884
87	Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1324-1332.	1.3	23
88	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). Journal of the American Academy of Dermatology, 2017, 77, 855-862.	0.6	104
89	Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. Journal of Cutaneous Medicine and Surgery, 2017, 21, 513-524.	0.6	39
90	The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). Journal of the European Academy of Dermatology and Venereology, 2017, 31, 507-517.	1.3	156

#	ARTICLE	IF	CITATIONS
91	Review of Systemic Treatment Options for Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 31-39.	0.6	42
92	Management of scalp psoriasis: current perspectives. Psoriasis: Targets and Therapy, 2016, 6, 33.	1.2	12
93	Predictors of Topical Use in Psoriasis Patients in the REFINE Study. Journal of Cutaneous Medicine and Surgery, 2016, 20, 106-112.	0.6	1
94	A Review of Psoriasis, Therapies, and Suicide. Journal of Cutaneous Medicine and Surgery, 2016, 20, 293-303.	0.6	37
95	2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. Journal of Cutaneous Medicine and Surgery, 2016, 20, 375-431.	0.6	28
96	Topical tofacitinib for atopic dermatitis: a phase II randomized trial. British Journal of Dermatology, 2016, 175, 902-911.	1.4	356
97	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Journal of the American Academy of Dermatology, 2016, 74, 134-142.	0.6	138
98	Treatment of Palmoplantar Pustulosis with the Combination of Ustekinumab and Apremilast: A Case Report. Archives of Case Reports in Clinical Medicine, 2016, 02, .	0.0	2
99	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). British Journal of Dermatology, 2015, 173, 1387-1399.	1.4	384
100	Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. BioDrugs, 2015, 29, 327-339.	2.2	50
101	The psychosocial impact of hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2015, 73, S19-S22.	0.6	73
102	Apremilast in the treatment of psoriasis and psoriatic arthritis. Skin Therapy Letter, 2015, 20, 1-6.	0.3	5
103	Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age. British Journal of Dermatology, 2014, 171, 1470-1477.	1.4	32
104	Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot. Blockchain in Healthcare Today, 0, , .	3.4	0